News Headlines

  1. Samsung Bioepis And Teva Expand Strategic Partnership To Advance Up To Six Potential Biosimilar Candidates 10/1/2026

    Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris2 (canakinumab).

  2. Piramal Pharma Solutions And NP2 To Complete Cyclophosphamide Development Phase Next Month 9/30/2026

    Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.

  3. OnDosis And Adare Pharma Solutions Announce Strategic Collaboration To Advance OnDosis's Lead U.S. ADHD Program 9/30/2026

    OnDosis AB (“OnDosis”), a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform, and Adare Pharma Solutions (“Adare”), a technology-driven, integrated contract development and manufacturing organization (CDMO), today announced a strategic collaboration.

  4. Serán Bioscience Strengthens Spray Dry Capabilities With Growth Investment From Biospring Partners To Accelerate Commercial Expansion And Meet Surging Customer Demand 9/30/2026

    Serán Bioscience (“Serán” or “the Company”), a leading contract development and manufacturing organization (CDMO) specializing in development, analytical and manufacturing solutions to pharmaceutical and biotechnology companies, today announced a growth investment led by Biospring Partners with continued participation from existing investors Vivo Capital, Bain Capital Life Sciences (“Bain Capital”), as well as Serán’s executive leadership.

  5. Hengrui Pharma And Novo Enter Exclusive License Agreement For Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596 9/29/2026

    Hengrui Pharma (600276.SH; 01276.HK) today announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

  6. TECPR2 Research Foundation And Forge Biologics Announce AAV Development And Manufacturing Partnership To Advance Gene Therapy For TECPR2 9/29/2026

    The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease.

  7. Merck Enters Into Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Oral KRAS G12D (ON) Inhibitor 9/28/2026

    Merck, known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.

  8. AstraZeneca Announces Strategic Equity Investment And Clinical Collaboration With Summit Therapeutics To Advance Leading ADC Combination Strategy In Cancer 9/28/2026

    AstraZeneca has entered into an agreement to invest $2B in newly issued equity in Summit Therapeutics Inc. to accelerate the development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody drug conjugates (ADCs) across tumour types.

  9. MindRank Partners With 3SBio To Commercialize Its AI-Designed Oral GLP-1 In China 9/28/2026

    MindRank AI Ltd. ("MindRank") today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. ("Mandi") and Zhejiang Wansheng Pharmaceutical Co., Ltd. ("Wansheng"), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist in a pivotal Phase 3 trial in China for obesity and overweight.

  10. Rottendorf Pharma Is CDMO Leadership Award Winner 2025 9/28/2026

    Thanks to overwhelmingly positive customer feedback, Rottendorf Pharma has been awarded the CDMO Leadership Award 2025 in the category of "Small Molecule Dosage Form - International."